Press Releases

All Releases
View Summary Five Prime Therapeutics to Present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology
Thursday, September 21, 2017
PDF 10.0 KB Add to Briefcase
View Summary Five Prime Presents Preclinical Research Data on Novel B7-H4 Therapeutic Antibody at ESMO 2017 Congress
Sunday, September 10, 2017
PDF 12.6 KB Add to Briefcase
View Summary Five Prime Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 at ESMO 2017 Congress
Sunday, September 10, 2017
PDF 16.3 KB Add to Briefcase
View Summary Five Prime Announces Abstract with Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 at ESMO 2017 Congress
Friday, September 1, 2017
PDF 14.9 KB Add to Briefcase
View Summary Five Prime to Feature Two Oral Data Presentations at ESMO 2017 Congress
Tuesday, August 29, 2017
PDF 11.0 KB Add to Briefcase
View Summary Five Prime Therapeutics Announces Addition of Bryan Irving, PhD, as Senior Vice President, Research
Thursday, August 17, 2017
PDF 12.5 KB Add to Briefcase
View Summary Five Prime Announces Second Quarter 2017 Results and Provides Business Update
Tuesday, August 8, 2017
PDF 29.7 KB Add to Briefcase
View Summary Five Prime Therapeutics to Announce Second Quarter 2017 Financial Results and Host Conference Call on August 8
Wednesday, July 26, 2017
PDF 9.1 KB Add to Briefcase
View Summary Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Clinical Safety Trial Evaluating FPA144 in Gastric Cancer in Japan in Preparation for Future Global Late-Stage Development
Monday, July 17, 2017
PDF 13.1 KB Add to Briefcase
View Summary Five Prime Therapeutics Announces Lewis T. "Rusty" Williams Plans to Transition from CEO to Executive Chairman of the Board in 2018
Wednesday, June 21, 2017
PDF 13.4 KB Add to Briefcase
View Summary Five Prime Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference
Monday, June 5, 2017
PDF 9.3 KB Add to Briefcase
View Summary Five Prime Therapeutics Presents Initial Clinical Trial Data from Phase 1/2 trial of Cabiralizumab in Pigmented Villonodular Synovitis (PVNS) at 2017 ASCO Annual Meeting
Sunday, June 4, 2017
PDF 15.8 KB Add to Briefcase
View Summary Five Prime Therapeutics Presents Updated Data From Phase 1 Trial of Single-Agent FPA144 at 2017 ASCO Annual Meeting
Saturday, June 3, 2017
PDF 64.3 KB Add to Briefcase
View Summary Five Prime Welcomes Garry Nicholson to Board of Directors
Monday, May 15, 2017
PDF 10.9 KB Add to Briefcase
View Summary Five Prime Announces First Quarter 2017 Results and Provides Business Update
Thursday, May 4, 2017
PDF 28.5 KB Add to Briefcase
View Summary Five Prime to Present Clinical Data at 2017 ASCO Annual Meeting
Thursday, April 20, 2017
PDF 11.0 KB Add to Briefcase
View Summary Five Prime Therapeutics to Announce First Quarter 2017 Financial Results and Host Conference Call on May 4
Thursday, April 20, 2017
PDF 9.1 KB Add to Briefcase
View Summary Five Prime Therapeutics Announces Completion of Enrollment for the Phase 2 Part of the Ongoing Trial of Cabiralizumab for the Treatment of Pigmented Villonodular Synovitis (PVNS)
Monday, April 10, 2017
PDF 12.0 KB Add to Briefcase
View Summary Five Prime Presents Data on Unique Immuno-Oncology Discovery Research at the 2017 AACR Annual Meeting
Monday, April 3, 2017
PDF 14.5 KB Add to Briefcase
View Summary Five Prime Presents Preclinical Research Data on CSF-1R and PD-1 Blockade at the 2017 AACR Annual Meeting
Monday, April 3, 2017
PDF 12.6 KB Add to Briefcase
Showing 1-20 of 181 Page: 1 2 3 4 5 ... 10  Next 20
Add to Briefcase = add release to Briefcase

FPRX (Common Stock)

Exchange
NASDAQ
Price
35.24
Change (%)
-0.50
Volume
166,565

Data as of 4:00 PM ET on Thursday, September 21, 2017
Minimum 20 minute delay
Refresh quote
Powered By eSignal, Inc.